Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05208281
Recruitment Status : Recruiting
First Posted : January 26, 2022
Last Update Posted : January 26, 2022
Sponsor:
Information provided by (Responsible Party):
AO GENERIUM

Brief Summary:
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.

Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis Type II Metabolic Diseases Drug: GNR-055 1.0-2.0-3.0 mg/kg Drug: GNR-055 2.0 mg/kg Drug: GNR-055 3.0 mg/kg Phase 2 Phase 3

Detailed Description:

GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.

GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II.

Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC "GENERIUM", Russia) in Patients With Mucopolysaccharidosis Type II
Actual Study Start Date : November 30, 2021
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : March 2025


Arm Intervention/treatment
Experimental: Adult: GNR-055
GNR-055: 1.0-2.0-3.0 mg/kg
Drug: GNR-055 1.0-2.0-3.0 mg/kg
Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Other Name: GNR-055

Experimental: Paediatric: GNR-055 2.0 mg/kg
GNR-055 2.0 mg/kg
Drug: GNR-055 2.0 mg/kg
Weekly IV infusion (lyophilized powder) 2.0 mg/kg
Other Name: GNR-055

Experimental: Paediatric: GNR-055 3.0 mg/kg
GNR-055 3.0 mg/kg
Drug: GNR-055 3.0 mg/kg
Weekly IV infusion (lyophilized powder) 3.0 mg/kg
Other Name: GNR-055




Primary Outcome Measures :
  1. Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline to Week 56 ]
    Safety assessment will be performed based on the subjective complaints, physical examination, assessment of vital signs, laboratory tests, and 12-lead ECG; Incidence of allergic and infusion-related reactions; Incidence of Anti-Drug Antibodies (ADAs) against GNR-055 and their neutralizing activity.

  2. Urine GAG excretion [ Time Frame: Baseline to Week 4, 8, 10, 26, and 52 ]
    Changes in levels of urine GAG excretion after multiple-dose administration of GNR-055


Secondary Outcome Measures :
  1. Serum concentration of the GNR-055 [ Time Frame: Week 52 ]
    Assessment of the serum concentration of GNR-055 and calculation of Cmax, AUC, T1/2, Cl et other parameters after multiple-dose administration

  2. GAG level in CerebroSpinal Fluid (CSF) [ Time Frame: Baseline to Week 6, 10, 26, and 52 ]
    Changes in levels of CSF GAG after multiple-dose administration of GNR-055

  3. Serum GAG level [ Time Frame: Baseline to Week 4, 8, 10, 26, and 52 ]
    Changes in levels of serum GAG after multiple-dose administration of GNR-055

  4. Large joint range of motion [ Time Frame: Week 8, 10, 26, and 52 ]
    Changes over time in the large joint range of motion after multiple-dose administration of GNR-055

  5. Liver and spleen volumes (MRI) [ Time Frame: Baseline to Week 8, 10, 26, and 52 ]
    Changes over time in liver and spleen volume according to ultrasound/MRI after multiple-dose administration of GNR-055

  6. 6-minute walk test [ Time Frame: Baseline to Week 8, 10, 26, and 52 ]
    Changes over time in the results of the 6-minute walk test after multiple-dose administration of GNR-055

  7. Left ventricular mass by EchoCG [ Time Frame: Baseline to Week 8, 10, 26, and 52 ]
    Changes over time in the left ventricular mass according to Echocardiography (Echo-CG) after multiple-dose administration of GNR-055

  8. Lung Forced Vital Capacity (FVC) [ Time Frame: Baseline to Week 8, Week 26, and Week 52 ]
    Changes over time in FVC according to spirometry after multiple-dose administration of GNR-055

  9. Neurocognitive functions assessment [ Time Frame: Baseline to Week 12, 26, and 52 ]
    Changes over time in neurocognitive functions after multiple-dose administration of GNR-055

  10. Brain white/gray matter structures (MRI) [ Time Frame: Baseline to Week 26, and 52 ]
    Changes over time in the quantitative MRI brain structure parameters after multiple-dose administration of GNR-055

  11. Serum neuromarkers [ Time Frame: Baseline to Week 24, and 52 ]
    Changes in levels of serum neuromarkers after multiple-dose administration of GNR-055

  12. CSF neuromarkers [ Time Frame: Baseline to Week 24, and 52 ]
    Changes in levels of CSF neuromarkers after multiple-dose administration of GNR-055



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed inform consent;
  • Verified diagnosis of MPS II (Hunter syndrome);
  • Naïve patients or patients who have received standard ERT whit idursulfase products;
  • No contraindications for lumbar puncture as judged by the Investigator;
  • Willingness and ability to follow study procedures.

Exclusion Criteria:

  • Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;
  • History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;
  • Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;
  • Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05208281


Contacts
Layout table for location contacts
Contact: Svetlana B. Korotkova, MD, PhD +7(495) 988 47 94 ext 7096 sbkorotkova@generium.ru
Contact: Oksana A. Markova, MD, MSc +7(495) 988 47 94 ext 7077 oamarkova@generium.ru

Locations
Layout table for location information
Russian Federation
State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital Recruiting
Ekaterinburg, Russian Federation, 620149
Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences) Not yet recruiting
Moscow, Russian Federation, 119333
V.I. Vernadsky Crimean Federal University Recruiting
Simferopol, Russian Federation, 295007
Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation Not yet recruiting
St. Petersburg, Russian Federation, 194100
State Budgetary Healthcare Institution Republican Medical Genetic Center Recruiting
Ufa, Russian Federation, 450076
Sponsors and Collaborators
AO GENERIUM
Investigators
Layout table for investigator information
Study Director: Oksana A. Markova, MD, MSc AO GENERIUM
Layout table for additonal information
Responsible Party: AO GENERIUM
ClinicalTrials.gov Identifier: NCT05208281    
Other Study ID Numbers: IDB-MPS-II-III
First Posted: January 26, 2022    Key Record Dates
Last Update Posted: January 26, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AO GENERIUM:
Mucopolysaccharidosis type II
Cognitive Dysfunction
Metabolic Diseases
Lysosomal Storage Diseases
Neurocognitive Disorders
Metabolism, Inborn
Genetic Diseases, Inborn
Neurobehavioral Manifestations
Neurologic Manifestations
Genetic Diseases, X-Linked
Hunter syndrome
Iduronate-2-sulfatase
Modified I2S protein
Connective Tissue Diseases
Mental Disorders
Intellectual Disability
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Cognition Disorders
Mental Retardation, X-Linked
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis II
Mucopolysaccharidoses
Metabolic Diseases
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Mucinoses
Connective Tissue Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System